Novo Nordisk stock

NOVO.B · Nasdaq Copenhagen · DKK

Compare Novo Nordisk
kr 275.50Change from previous close: −3.42%Absolute change: −kr 9.75

Close · November 17, 2026

Price history

−10.22% over the period

1 year: from kr 312.70 (November 17, 2025) to kr 280.75 (November 17, 2026), −10.22%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026kr 280.75
October 30, 2026kr 266.10
September 30, 2026kr 253.20
August 31, 2026kr 292.40
July 31, 2026kr 306.50
June 30, 2026kr 314.60
May 29, 2026kr 292.95
April 30, 2026kr 272.25
March 31, 2026kr 230.90
February 27, 2026kr 237.90
January 30, 2026kr 369.55
December 30, 2025kr 325.25
November 28, 2025kr 317.00
November 17, 2025kr 312.70

At a glance

  • The company

    Researches, develops, manufactures and distributes pharmaceutical products for obesity, diabetes, rare diseases and other therapeutic areas

  • Latest results

    Quarter to September 30, 2026 · EPS kr 5.79 (estimate kr 4.69)

TickerLandia's take on Novo Nordisk

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 224.25
52-wk highkr 409.95

−32.80% from the 52-week high

Analysts · 26 analysts

Average targetkr 299.91+8.86% vs. price

Buy 5 · Hold 15 · Sell 6 · Hold

TickerLandia Fingerprint: Novo Nordisk

Compared with similar companies: very high profitability.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Novo Nordisk is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Novo Nordisk's P/E today is 12.2, below the median of its last 10 fiscal years (23.6; between 14.1 and 38.4 from 2016 to 2025). Novo Nordisk's P/E (trailing 12 months): 11.2, −48% against the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Novo Nordisk's metrics compared with similar companies
MetricNovo NordiskPosition in the groupBand
P/E (trailing 12 months)11.2Low
Forward P/E12.5Middle
Operating margin50.8%High
ROE58.4%High
Debt/equity0.62Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Novo Nordisk. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 79.2B

Latest quarter · Q3 2026

Net income

kr 16.74B

Latest quarter · Q3 2026

Quarterly net margin

21.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
kr 1.26T
P/E
11.2
EPS
kr 25.49
Volume
4.61M
Daily trading
€189.57M
Dividend yield
4.25%
Last ex-dividend on August 14, 2026

How Novo Nordisk is changing

All results
  • Revenue grew 19.5% a year on average over the last 5 years

  • Operating margin rose from 42.7% to 45.5%

  • Free cash flow equal to 75% of net income

Returns

Novo Nordisk returns with dividends

kr 1,000 invested in Novo Nordisk 5 years ago, on November 17, 2021, would be worth kr 835 today with dividends reinvested: −16.55% in total, −3.55% per year. On price alone it would be kr 745 (−25.49%).

PeriodNovo Nordiskkr 1,000 becomes
1 month+9.45%kr 1,095
6 months−7.92%kr 921
Year to date−13.68%kr 863
1 year−5.91%kr 941
3 years−55.94%kr 441
5 years−16.55%kr 835
10 years+208.73%kr 3,087

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Novo Nordisk: technical analysis

Novo Nordisk shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 73.2% below its all-time closing high (kr 1,028.00, June 25, 2024).

Trend
No clear trend
RSI (14 sessions)
55
Between 30 and 70
vs 200-session average
−2.04%

Support and resistance

Price areas where Novo Nordisk has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistancekr 297.25+7.89%3 touches, last on May 29, 2026
  2. Resistancekr 287.35+4.30%5 touches, last on November 4, 2026
  3. Resistancekr 277.88+0.86%2 touches, last on June 18, 2026
  4. Last pricekr 275.50
  5. Supportkr 265.38−3.68%4 touches, last on October 22, 2026
  6. Supportkr 255.30−7.33%2 touches, last on October 29, 2026
  7. Supportkr 244.72−11.17%3 touches, last on October 5, 2026

Volatility and risk

Volatility (60 sessions, annualised)
32.9%
Largest fall in the last year
−43.07%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Novo Nordisk: seasonality

Average monthly price change over 26 years

+2.0%Jan+2.9%Feb+0.7%Mar+17.2%Apr+0.8%May+2.6%Jun−0.9%Jul+2.4%Aug−1.9%Sep+0.5%Oct+2.8%Nov+1.1%Dec

Over the last 26 years, the strongest month for Novo Nordisk has been April: +17.18% on average, positive in 19 years out of 26. The weakest has been September: −1.88% on average, positive in 10 years out of 26. November, the current month, has been positive in 19 years out of 25 (+2.80% on average).

Show chart data
MonthAverageMedianPositive years
January+2.01%+0.53%13 of 25
February+2.90%+4.90%19 of 26
March+0.69%−0.11%12 of 26
April+17.18%+3.00%19 of 26
May+0.78%+1.74%16 of 26
June+2.56%+2.63%15 of 26
July−0.94%−1.02%10 of 26
August+2.41%+1.64%14 of 26
September−1.88%−1.22%10 of 26
October+0.48%+0.95%15 of 26
November+2.80%+2.23%19 of 25
December+1.07%+1.66%20 of 25

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Novo Nordisk and its competitors

Employing 68,794 people, Novo Nordisk develops, manufactures and sells medicines, with diabetes care, weight management and rare diseases at the core of its portfolio. Products include insulin pens, some with digital dose-guidance features, growth hormone pens, injection needles and the Wegovy pill, an oral treatment for weight management. Customers are reached in Europe, North America, Japan, Korea, Oceania, Southeast Asia, China, Hong Kong, Taiwan, Latin America, the Middle East and Africa.

Headquarters
Bagsvaerd, Denmark
Employees
68,794
Founded
1923
Chief executive
Maziar Doustdar
Novo Nordisk and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Novo NordiskNOVO.B$184.87B50.8%11.2−7.92%
SanofiSAN$116.52B22.3%25.5+17.04%
AstraZenecaAZN$287.12B25.8%26.6+1.25%
NovartisNOVN$305.16B34.0%32.6+14.23%
GSKGSK$102.04B30.5%18.0+0.35%
Roche HoldingROP$387.48B33.1%26.7+25.84%

Same industry or related industries, similar size. Compare Novo Nordisk with its competitors · Full profile